Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib and ctDNA-Guided De-Escalation in HR+/HER2- Early Breast Cancer
NCT06970912Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Peking University People's Hospital. Started Aug 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06970912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970912.